SCHEMBL14728111

SCHEMBL14728111

CCn1c2ccccc2c2cc3c4ccc(N(c5cccc6ccccc56)c5cccc6ccccc56)cc4c4ccccc4c3cc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.43
MAPT P10636 4/20 0.43
HTT P42858 3/20 0.43
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
ALDH1A1 P00352 3/20 0.43
HPGD P15428 2/20 0.43
MAPK1 P28482 2/20 0.43
HBB P68871 1/20 0.43
HSD17B10 Q99714 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
POLB P06746 2/20 0.41
PKM P14618 1/20 0.41
KDM1A O60341 1/20 0.40
NPY5R Q15761 3/20 0.39
LMNA P02545 3/20 0.39
NPSR1 Q6W5P4 2/20 0.38
PER2 O15055 1/20 0.38
CRY1 Q16526 1/20 0.38
CRY2 Q49AN0 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14728109 0.95 KDM1A (0.41) KDM4EMAPTHTTMEN1KMT2A
SCHEMBL14728115 0.93 MAPT (0.40) KDM4EMAPTHTTMEN1KMT2A
SCHEMBL14728120 0.92 NPY5R (0.41) KDM4EMAPTHTTMEN1KMT2A
SCHEMBL14728119 0.86 MAPT (0.34) KDM4EMAPTHTTMEN1KMT2A
SCHEMBL6604512 0.85 KDM4E (0.48) KDM4EMAPTHTTMEN1KMT2A
SCHEMBL14728123 0.85 KDM4E (0.45) KDM4EMAPTHTTMEN1KMT2A
SCHEMBL14728107 0.85 KDM4E (0.49) KDM4EMAPTHTTMEN1KMT2A
SCHEMBL12181004 0.81 KDM4E (0.46) KDM4EMAPTHTTMEN1KMT2A
SCHEMBL14004044 0.81 NPY5R (0.40) KDM4EMAPTHTTMEN1KMT2A
SCHEMBL14728121 0.81 NPY5R (0.43) KDM4EMAPTHTTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9017829-B2 Phenanthrocarbazole compound, and organic electroluminescent device using same DOOSAN CORPORATION (KR) 2015-04-28 US disclosed
US-9017829-B2 Phenanthrocarbazole compound, and organic electroluminescent device using same DOOSAN CORPORATION (KR) 2015-04-28 US disclosed
US-20130048975-A1 PHENANTHROCARBAZOLE COMPOUND, AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME DOOSAN CORPORATION (KR) 2013-02-28 US disclosed
US-20130048975-A1 PHENANTHROCARBAZOLE COMPOUND, AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME DOOSAN CORPORATION (KR) 2013-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130048975-A1 PHENANTHROCARBAZOLE COMPOUND, AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME PPOX, ORC3, CACNA2D3 KDM4E 1626/4885MAPT 589/4885HTT 1001/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.